RAPT News & Analysis
2 articles
Market Mood
Rapport Therapeutics stock reaches all-time high of 42.36 USD
Rapport Therapeutics (RAPT) has reached an all-time high stock price of 42.36 USD. This significant milestone indicates strong investor interest and may influence market perceptions of the company's growth potential. The rise in stock price could attract more traders and investors looking for profitable opportunities. Understanding patterns like this can provide insights into market trends for biotech stocks.
Read More: Rapport Therapeutics stock reaches all-time high of 42.36 USD
Biotech M&A Reaches $106 Billion in 2026 Amid Strong Momentum
Global biopharma M&A has reached $106 billion across 201 deals in 2026, positioning it for the strongest year since pre-COVID, according to PitchBook data. If the pace continues, total deal value could exceed $250 billion by year-end. The average deal value has increased to $527.3 million from $365 million in 2025, driven by strategic acquisitions. Major companies are focusing on 'bolt-on' deals in the $1 billion to $5 billion range, with GSK's $2.2 billion acquisition of RAPT Therapeutics exemplifying this trend.
Read More: Biotech M&A Reaches $106 Billion in 2026 Amid Strong Momentum